Form 4: Vericel Director Executes Stock Option Exercise and Sale
Statement of Changes in Beneficial Ownership
Vericel Corporation Director Kevin F. McLaughlin exercised 7,000 stock options and sold the resulting shares under a Rule 10b5-1 plan.
Summary
- Director Kevin F. McLaughlin exercised options for 7,000 shares of Vericel Corporation (VCEL) common stock on May 13, 2026.
- The exercise involved two tranches of 3,500 shares each, with strike prices of $2.63 and $13.05.
- Following the exercise, the director sold the 7,000 shares at prices ranging between $32.82 and $32.83 per share.
- The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard equity compensation management by a director.
Positives
- The director maintains a remaining beneficial ownership of 18,300 shares of common stock.
- The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating systematic rather than reactive selling.
Negatives
- The director reduced their direct beneficial ownership position through the sale of the exercised shares.
Risks
- Continued reliance on Rule 10b5-1 plans for liquidity may signal ongoing divestment by insiders.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector as executives and directors manage personal portfolios and exercise long-dated equity compensation.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate insiders to avoid allegations of trading on material non-public information.
Stakeholder Impact
- Minimal impact on shareholders as the sale was executed through a pre-planned 10b5-1 arrangement.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/03/2017 | Original grant date of the first tranche of stock options. |
| 05/02/2018 | Original grant date of the second tranche of stock options. |
| 05/12/2025 | Date the Rule 10b5-1 trading plan was adopted. |
| 05/13/2026 | Date of the option exercise and subsequent share sales. |
| 05/15/2026 | Date the Form 4 was signed and filed. |
Keywords
Vericel, VCEL, Insider Trading, Form 4, Stock Options, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.